Zhai Ya-Ling, Meng Si-Jun, Zhu Li, Shi Su-Fang, Wang Su-Xia, Liu Li-Jun, Lv Ji-Cheng, Yu Feng, Zhao Ming-Hui, Zhang Hong
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; and Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Institute of Nephrology, Peking University, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; and Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China
J Am Soc Nephrol. 2016 Sep;27(9):2894-905. doi: 10.1681/ASN.2015010012. Epub 2016 Jan 29.
A recent genome-wide association study of IgA nephropathy (IgAN) identified 1q32, which contains multiple complement regulatory genes, including the complement factor H (CFH) gene and the complement factor H-related (CFHRs) genes, as an IgAN susceptibility locus. Abnormal complement activation caused by a mutation in CFHR5 was shown to cause CFHR5 nephropathy, which shares many characteristics with IgAN. To explore the genetic effect of variants in CFHR5 on IgAN susceptibility, we recruited 500 patients with IgAN and 576 healthy controls for genetic analysis. We sequenced all exons and their intronic flanking regions as well as the untranslated regions of CFHR5 and compared the frequencies of identified variants using the sequence kernel association test. We identified 32 variants in CFHR5, including 28 rare and four common variants. The distribution of rare variants in CFHR5 in patients with IgAN differed significantly from that in controls (P=0.002). Among the rare variants, in silico programs predicted nine as potential functional variants, which we then assessed in functional assays. Compared with wild-type CFHR5, three recombinant CFHR5 proteins, CFHR5-M (c.508G>A/p.Val170Met), CFHR5-S (c.533A>G/p.Asn178Ser), and CFHR5-D (c.822A>T/p.Glu274Asp), showed significantly higher C3b binding capacity (CFHR5-M: 109.67%±3.54%; P=0.02; CFHR5-S: 174.27%±9.78%; P<0.001; CFHR5-D: 127.25%±1.75%; P<0.001), whereas another recombinant CFHR5 (c.776T>A/p.Leu259Termination) showed less C3b binding (56.89%±0.57%; P<0.001). Our study found that rare variants in CFHR5 may contribute to the genetic susceptibility to IgAN, which suggests that CFHR5 is an IgAN susceptibility gene.
最近一项针对IgA肾病(IgAN)的全基因组关联研究确定了1q32,该区域包含多个补体调节基因,包括补体因子H(CFH)基因和补体因子H相关(CFHRs)基因,是一个IgAN易感位点。研究表明,CFHR5突变引起的补体异常激活会导致CFHR5肾病,其与IgAN有许多共同特征。为了探究CFHR5基因变异对IgAN易感性的遗传效应,我们招募了500例IgAN患者和576例健康对照进行遗传分析。我们对CFHR5的所有外显子及其内含子侧翼区域以及非翻译区进行了测序,并使用序列核关联检验比较了所鉴定变异的频率。我们在CFHR5中鉴定出32个变异,包括28个罕见变异和4个常见变异。IgAN患者中CFHR5罕见变异的分布与对照组有显著差异(P=0.002)。在这些罕见变异中,计算机程序预测有9个为潜在的功能变异,我们随后在功能试验中对其进行了评估。与野生型CFHR5相比,三种重组CFHR5蛋白,即CFHR5-M(c.508G>A/p.Val170Met)、CFHR5-S(c.533A>G/p.Asn178Ser)和CFHR5-D(c.822A>T/p.Glu274Asp),表现出显著更高的C3b结合能力(CFHR5-M:109.67%±3.54%;P=0.02;CFHR5-S:174.27%±9.78%;P<0.001;CFHR5-D:127.25%±1.75%;P<0.001),而另一种重组CFHR5(c.776T>A/p.Leu259Termination)的C3b结合较少(56.89%±0.57%;P<0.001)。我们的研究发现,CFHR5中的罕见变异可能导致IgAN的遗传易感性,这表明CFHR5是一个IgAN易感基因。